

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 781 561 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
02.07.1997 Bulletin 1997/27

(51) Int. Cl.⁶: **A61K 45/00**, A61K 31/415,
A61K 31/435

(21) Application number: **95930029.4**

(86) International application number:
PCT/JP95/01745

(22) Date of filing: **31.08.1995**

(87) International publication number:
WO 96/09069 (28.03.1996 Gazette 1996/14)

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **19.09.1994 JP 251521/94**

(71) Applicant: **FUJISAWA PHARMACEUTICAL CO.,
LTD.
Osaka-shi Osaka 541 (JP)**

(72) Inventors:
• **NOMURA, Kazuhiko**
Ibaraki 305 (JP)
• **YAMAGUCHI, Isamu**
Hyogo 666-01 (JP)

(74) Representative: **Türk, Gille, Hrabal, Lelfert**
Brucknerstrasse 20
40593 Düsseldorf (DE)

(54) **NOVEL MEDICINAL USE OF 5HT₃ ANTAGONIST**

(57) An impotence remedy containing a 5HT₃
antagonist as the active ingredient.

EP 0 781 561 A1

Description

TECHNICAL FIELD

5 The present invention relates to a therapeutic agent for impotence which comprises a 5HT₃ antagonist as the active ingredient, and is useful in the medical field.

BACKGROUND ART

10 5HT receptors are classified into the subtypes of 5HT₁, 5HT₂, 5HT₃, 5HT₄, 5HT₅, 5HT₆ and 5HT₇ (see D. Hoyer et al., Pharmacol. Rev., 1994 in press; P.P.A. Humphrey et al., Trends Pharmacol. Sci., 14, 233, 1993).

It is reported that 5HT₁ receptors are densely distributed in smooth muscle, cerebral cortex, hippocampus, ventral horn of spinal cord, basal ganglia, etc., and are involved in the depression of nervous system and in the modulation of cardiovascular system (e.g., hypotension, tachycardia, dilation and contraction of vascular smooth muscle) and so on;

15 that 5HT₂ receptors are densely distributed in smooth muscle, motor cortex, etc., and are involved in the depolarization of motor nerve, modulation of body temperature, hypertension, vasoconstriction and the contraction of smooth muscle in digestive tract, trachea and vesica; and

that 5HT₃ receptors are densely distributed in both peripheral and central nervous system including human cerebral cortex, etc., and are involved in the expression of emesis and the attack of hemicrania (see A.H. Dickenson's review on 5HT).

20 Recently, the need for a therapeutic agent for impotence has been growing clinically. Although there is a therapeutic method for impotence in which vasoactive drugs such as papaverine or PGE₁ are injected directly in corpus cavernosum, this method is not desirable because of some undesirable side effects or the methodology. Consequently, the development of an effective oral therapeutic agent for impotence has been needed. Up to the present, however, the effects of conventional oral drugs which were considered to be beneficial for impotence has been proved to be unsatisfactory, because of their poor efficacy, their safety, or undesirable side effects.

It has been reported that 5HT (serotonin) is involved in the expression of sexual behavior (see Gessa GL, Tangliamonte A, In Sexual Behavior, Pharmacology and Biochemistry, edited by Sandler Mand, Gessa GL, New York; Raven Press, 1975). On the other hand, regarding the relationship between 5HT₃ receptors and sexual behavior, it is reported that 5HT₃ antagonist had no effect on sexual behavior in normal (non-stressed) animals (see Stoessl AJ et al., Brain Res. 517, 111, 1990; Tanco SA et al., Experimentia 49, 238, 1991).

The object of the present invention is to provide a novel and effective medicine for the treatment of impotence.

DISCLOSURE OF THE INVENTION

35 We, the inventors of the present invention, found that a 5HT₃ antagonist is effective for the treatment of impotence, and have completed the present invention on the basis of this finding.

Specifically, the present invention relates to a therapeutic agent for impotence which comprises a 5HT₃ antagonist as an active ingredient.

40 The 5HT₃ antagonist as referred to this invention includes a drug having a stronger antagonistic effect against 5HT₃ receptors (for example, those existing in human cerebral cortex) than its antagonistic effect against 5HT₁ receptors (for example, those existing in mouse ventral spinal marrow) and 5HT₂ receptors (for example, those existing in human smooth muscle). The receptor antagonist is abbreviated as an antagonist in this invention.

Preferred examples of the 5HT₃ antagonist are endo-1H-indole-3-carboxylic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (common name, Tropisetron), endo-3,5-dichlorobenzsoic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (common name, Bemisetron), 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one · hydrochloride dihydrate (common name, Ondansetron), endo-1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H-indazole-3-carboxamide (common name, Granisetron), (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole · hydrochloride (common name, YM-060), (+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one · hydrochloride (common name, FK1052), (+)-3,4-dihydro-5-methyl-2-[1-(5-methyl-1H-imidazol-4-yl)ethyl]pyrimido[1,6-a]indol-1(2H)-one · hydrochloride (common name, FR), etc., which, however, are not limitative, but any other known or novel 5HT₃ antagonists can be used in the present invention. For example, compounds disclosed in the following patent publications are known. European Patent Laid-Open No.0189002A, European Patent Laid-Open No.067770A, European Patent Laid-Open 0191562A, European Patent Laid-Open No.0200444A, European Patent Laid-Open No.0381422A, European Patent Laid-Open No.0361317A, European Patent Laid-Open No.0420086A.

The 5HT₃ antagonist may include pharmaceutically-acceptable salts thereof. Pharmaceutically-acceptable salts are commonly used non-toxic salts, including, for example, inorganic acid salts (e.g., hydrochlorides, hydrobromides, sulfates, phosphates), organic acid salts (e.g., formates, acetates, trifluoroacetates, oxalates, maleates, fumarates, tar-

trates, methanesulfonates, benzenesulfonates, toluenesulfonates), alkali metal salts (e.g., sodium salts, potassium salts), alkaline earth metal salts (e.g., calcium salts), and salts with amino acids (e.g., arginine salts, aspartates, glutamates).

The known compounds which mentioned hereinabove as examples of the 5HT₃ antagonist for use in the present invention can be prepared by the methods described in the above-mentioned publications or by any known methods.

Where the 5HT₃ antagonist includes stereoisomers with asymmetric carbon atom(s), the individual stereoisomers and their mixtures are also within the scope of the 5HT₃ antagonist for use in the present invention.

The 5HT₃ antagonist can be administered orally, parenterally (including for intravenous injection, subcutaneous injection and intramuscular injection) or externally (locally), in any form of ordinary pharmaceutical preparations of, for example, capsules, microcapsules, soft capsules, tablets, granules, powdery preparations, powders, troches, pills, ointments, emulsions, suppositories, injections, liquids, suspensions, syrups, elixirs, or limonades. Wherein, preferred one is oral administration of the 5HT₃ antagonist.

The pharmaceutical preparations mentioned above can be prepared by any ordinary methods using any ordinary organic and inorganic carriers known for formulation of medicines, for example, vehicles such as sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate; binding agents such as cellulose, methyl cellulose, hydroxymethyl cellulose, polypropylpyrrolidone, gelatin, arabic gum, polyethylene glycol, sucrose, starch; disintegrators such as starch, carboxymethyl cellulose, hydroxypropyl starch, sodium hydrogencarbonate, calcium phosphate, calcium citrate; lubricants such as magnesium stearate, aerosil, talc, sodium laurylsulfate; flavorings such as citric acid, menthol, glycine, orange powder; preservatives such as sodium benzoate, sodium bisulfite, methylparaben, propylparaben; stabilizers such as citric acid, sodium citrate, acetic acid; suspending agents such as methyl cellulose, polyvinyl pyrrolidone, aluminium stearate; dispersants such as hydroxypropylmethyl cellulose; diluents such as water; base waxes such as cacao butter, white petrolatum, polyethylene glycol, etc. The amount of the active ingredient to be in the pharmaceutical preparations may be one that is sufficient for producing the intended curing effect, and, for example, may be from 0.001 µg/kg to 1 mg/kg for oral or parenteral administration.

The 5HT₃ antagonist may be administered, in general, with in a unit dose of from 0.05 µg/body to 50 mg/body once to four times a day. However, the above dose may be increased or decreased, depending on the age and the body weight and condition of the patient or on the administration route.

EXAMPLES

Now, the present invention is described in more detail herein under with reference to the following test example and example, which, however, is not intended to restrict the scope of the invention.

Test Example:

Beneficial Effect of 5HT₃ Antagonists on Copulatory Disorder in Male Mice induced by Psychosocial Stress

(1) Experimental Method:

Postpubertal male ICR mice (8 weeks) were individually housed and the isolation housing continued for 4 weeks. Then, they were confronted with estrus female mice and the copulatory behavior of male mice was measured for 10 minutes. The experiment was carried out under red dim illuminations. The control mice were group-housed for 4 weeks. The tested compounds described below were administered orally to the male mice one hour before the behavioral testing. Solvent (distilled water or 0.5% methyl cellulose solution) was administered to the vehicle-treated mice of isolated group (dose of 0ug/kg). The frequency of copulatory elements (mounting and intromission) during the testing were measured and analyzed.

(2) Tested compounds:

Tropisetron, Bemisetron, Granisetron, Ondansetron, YM-060 and FK1052

(3) Experimental Results:

The beneficial effects of these six 5HT₃ antagonists on stress-induced copulatory disorder in male mice are shown in Table 1.

Table 1

Effects of 5HT₂ antagonists on Copulatory Disorder
in Male Mice

Frequency of Copulatory Behavior in 10 Minutes' Testing [times] : Mean \pm S.E. [Incidence, %]		
Group (number of mice tested)	Mounting	Intromission
Control Group (16)	6.12 \pm 1.07 [94]	6.31 \pm 1.87 [94*]
Tropisetron		
0 μ g/kg (16)	2.25 \pm 0.50 ^b [75]	1.25 \pm 0.39* [50]
0.1 μ g/kg (8)	3.88 \pm 1.09 [75]	2.38 \pm 0.91 [75]
1 μ g/kg (8)	6.00 \pm 1.31 [88]	4.88 \pm 1.29 [88]
10 μ g/kg (16)	7.19 \pm 1.45 ^a [88]	6.06 \pm 1.19 ^a [88]
Control Group (8)	5.75 \pm 0.73 [100]	3.75 \pm 1.00 [88]
Bemesetron		
0 μ g/kg (8)	1.88 \pm 0.74 ^b [63]	1.25 \pm 0.53* [63]
1 μ g/kg (8)	4.88 \pm 0.95 [100]	3.12 \pm 0.67 [88]

5

10

15

20

25

30

35

40

45

50

55

Control Group (10)	5.80 ± 1.47 [70]	4.80 ± 1.40 [70]
Granisetron		
0 μ g/kg (10)	$1.30 \pm 0.60^*$ [40]	$0.90 \pm 0.43^*$ [40]
0.1 μ g/kg (10)	3.30 ± 1.07 [60]	2.80 ± 0.96 [60]
1 μ g/kg (10)	4.90 ± 1.67 [60]	3.60 ± 1.20 [60]
10 μ g/kg (10)	4.70 ± 1.62 [80]	5.20 ± 2.09 [60]
100 μ g/kg (10)	6.20 ± 1.22 [100 ^a]	3.20 ± 0.74 [80]
Ondansetron		
Control Group (10)	5.70 ± 0.97 [100]	4.50 ± 1.00 [90]
0 μ g/kg (10)	$2.70 \pm 0.92^*$ [70]	$1.90 \pm 0.66^*$ [60]
1 μ g/kg (10)	4.80 ± 1.03 [80]	3.40 ± 0.99 [70]
10 μ g/kg (10)	5.60 ± 2.37 [60]	4.30 ± 1.71 [50]
100 μ g/kg (10)	6.00 ± 0.70 [100]	4.80 ± 1.38 [100 ^a]

Control Group (12)	6.36 ± 01.82 [100]	5.91 ± 1.16 [100*]
YM - 060		
0 µg/kg (12)	2.91 ± 1.00 [64]	1.73 ± 0.56 ^b [55]
0.01 µg/kg (12)	3.55 ± 0.64 [91]	3.27 ± 0.69 [91]
0.1 µg/kg (12)	3.09 ± 0.86 [73]	2.09 ± 0.62 [64]
1 µg/kg (12)	4.82 ± 1.30 [82]	4.00 ± 1.05 [82]
10 µg/kg (12)	6.00 ± 1.67 [91]	3.73 ± 1.03 [82]
FK1052		
0 µg/kg (10)	2.20 ± 0.71 ^b [70]	1.30 ± 0.45 ^b [60]
0.1 µg/kg (10)	3.80 ± 0.83 [90]	2.90 ± 0.75 [80]
1 µg/kg (10)	6.10 ± 1.77 [90]	4.00 ± 1.41 [70]
10 µg/kg (10)	5.70 ± 1.18 [100]	4.40 ± 1.48 [80]

*P < 0.05, ^bP < 0.01 vs Control Group (Student's t - test)

^aP < 0.01 vs 0 µg/kg (Dunnett's test)

^aP < 0.05, ^aP < 0.01 vs 0 µg/kg (Fisher's exact probability test)

Since individual housing completely deprives the male mice of social stimulation, this model is considered to be one of the established psychosocial stress models. As shown in Table 1, the two copulatory elements, mounting and intromission, in individually-housed male mice were significantly depressed than those in group-housed control mice. All the six 5HT₃ antagonists tested herein exerted a curative effect on copulatory disorder induced by psychosocial stress. Consequently, it is expected that 5HT₃ antagonists have a curative or an ameliorating effect on various stress-induced diseases, for example, male sexual disorder such as impotence and bradyspermatism, and women's dyspareunia and frigidity; eating disorder such as hyperphagia and apastia; digestive disorders such as gastric erosion and gastric ulcer; sleep disorder such as sleeplessness; mental disorder such as melancholia and maternity blue; equivocal

EP 0 781 561 A1

complaint; circular system disorder such as stress-induced hypertension; and any other various stress-induced diseases.

A formulation of the medicine of the invention is exemplified below.

5 Example 1 (capsules):

10

FK1052	5 mg
Lactose	80 mg

15 These were mixed and encapsulated into a commonly used hard gelatin capsule.

Advantages of the invention:

20 From the test results hereinabove, it is understood that 5HT₃ antagonist exerts an extremely excellent restoring effect on copulatory disorder induced by psychosocial stress, and are useful as a therapeutic agent for impotence for human being and animals.

Claims

- 25 1. A therapeutic agent for impotence which comprises 5HT₃ antagonist as an active ingredient.
2. A use of 5HT₃ antagonist as a therapeutic agent for impotence.
3. A method for treating impotence which comprises administering an effective amount of 5HT₃ antagonist.

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP95/01745

A. CLASSIFICATION OF SUBJECT MATTER		
Int. C16 A61K45/00, A61K31/415, A61K31/435		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Int. C16 A61K45/00, A61K31/415, A61K31/435		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CAS ONLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	AMBROSI, B. Effect of serotonin antagonists in sexually impotent men. Andrologia. 1979, Vol. 11, No. 6, pages 475-477	1 - 3
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "T" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
November 20, 1995 (20. 11. 95)		December 2, 1995 (12. 12. 95)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)